Previous transurethral resection of the prostate is not a contraindication to high‐dose rate brachytherapy for prostate cancer
Authors:
- 10 November 2009
- journal article
- Published by Wiley in BJU International
- Vol. 104 (11) , 1620-1623
Abstract
OBJECTIVE: To analyse retrospectively the morbidity and efficacy of high‐dose rate (HDR) brachytherapy in patients who had a previous transurethral resection of the prostate (TURP). PATIENTS AND METHODS: Morbidities documented in the records of 32 patients with previous TURP and 106 with no previous TURP, treated with HDR brachytherapy for prostate cancer at our institution, were analysed and compared. All patients received HDR brachytherapy as a boost before conformal external beam radiotherapy. We recorded and analysed genitourinary complications, rectal morbidity, and the biochemical control rate as assessed by the prostate‐specific antigen (PSA) level. RESULTS: All complications of patients who received HDR brachytherapy were recorded during the follow‐up. All gastrointestinal and genitourinary complications were not significantly different in patients with or without previous TURP. There was little incontinence or severe morbidity associated with HDR brachytherapy. The PSA‐based biochemical control rates were similar in patients with or without previous TURP in each risk group. CONCLUSIONS: HDR brachytherapy is a reasonable treatment for localized prostate cancer in patients who have had a previous TURP, with the expectation of low morbidity and satisfactory biochemical control.Keywords
This publication has 14 references indexed in Scilit:
- Comparison of the Outcome and Morbidity for Localized or Locally Advanced Prostate Cancer Treated by High-dose-rate Brachytherapy Plus External Beam Radiotherapy (EBRT) Versus EBRT AloneJapanese Journal of Clinical Oncology, 2008
- Low Morbidity Following High Dose Rate Brachytherapy in the Setting of Prior Transurethral Prostate ResectionJournal of Urology, 2007
- High-Dose-Rate Brachytherapy Plus External Beam Radiotherapy for T1 to T3 Prostate Cancer: An Experience in TaiwanUrology, 2007
- Six year experience of external beam radiotherapy, brachytherapy boost with a 1Ci 192Ir source, and neoadjuvant hormonal manipulation for prostate cancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus ConferenceInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy’s 10-year resultsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2005
- Effect of cigarette smoking on biochemical outcome after permanent prostate brachytherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004
- High dose rate 192Iridium brachytherapy in localized prostate cancer: Results and toxicity with maximum follow-up of 10 yearsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2000
- Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resectionInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1997
- Overview: Late effects of normal tissues (LENT) scoring systemInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1995